Arcus Biosciences, Inc. (RCUS)
Free
No email, no account, no signup.
Pulling latest news for Arcus Biosciences, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NYSE
Type
Biotech
Sector
Biotechnology and cancer immunotherapy
Market Cap
$3.3B
We're already tracking Arcus Biosciences, Inc. — here are the latest events we've registered
Recent News
- On May 5, 2026, Arcus reported Q1 2026 results and announced the discontinuation of its Phase 3 STAR-121 lung cancer trial for futility. The company also noted that Gilead Sciences will not exercise its broad option rights in July 2026, though existing collaborations continue. Arcus ended the quarter with $876 million in cash, providing a runway into late 2028.
Want to know how this news affects Arcus Biosciences, Inc.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Arcus Biosciences, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.